RxDoctor Payments Data

Sanjay Nariani, MD

Internal Medicine · Suwanee, GANPI 1184836488

Payments from drug & device makers

$3,126in general payments, 2019–2025

Across 138 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$417
  • Bayer$345
  • Lilly USA, LLC$339
  • Merck$164
  • Astellas Pharma US Inc$108
  • plus $663 from 14 others

What the payments were for

  • Food & beverage$3,02097%
  • Education$1063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,126 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$235,464
Medicare patients
361
Services billed
2,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban295$86,977
JardianceEmpagliflozin61$78,024
CreonLipase/Protease/Amylase54$44,549
OzempicSemaglutide31$44,465
FarxigaDapagliflozin Propanediol43$35,465
MounjaroTirzepatide14$26,852
XareltoRivaroxaban85$20,733
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$11,735
TradjentaLinagliptin17$11,576
RybelsusSemaglutide11$11,550
MyrbetriqMirabegron24$11,398
SymbicortBudesonide/Formoterol Fumarate28$7,391
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$6,224
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$5,962
ArexvyRsvpref3 Antigen/As01e/Pf18$5,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$72$89,60078 claims
PfizerEliquis$98$86,977295 claims
Novo NordiskOzempic, Rybelsus$1,090$56,01542 claims
AbbVieCreon, Lumigan$30$48,61669 claims
AstraZenecaFarxiga, Symbicort$417$42,85671 claims
Lilly USA, LLCMounjaro$339$26,85214 claims
Johnson & JohnsonXarelto$77$20,73385 claims
Astellas Pharma US IncMyrbetriq$108$11,39824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Suwanee

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →